CRIS Current Research Information System

DE GIORGI, UGO FEDERICO FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.312
NA - Nord America 2.255
EU - Europa 1.423
SA - Sud America 219
AF - Africa 154
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.374
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.178
VN - Vietnam 1.177
SG - Singapore 1.144
CN - Cina 861
HK - Hong Kong 504
IT - Italia 383
DE - Germania 325
BD - Bangladesh 196
BR - Brasile 154
KR - Corea 136
FR - Francia 124
NL - Olanda 118
SE - Svezia 107
FI - Finlandia 78
IN - India 76
GB - Regno Unito 74
JP - Giappone 52
CI - Costa d'Avorio 46
IE - Irlanda 44
CA - Canada 42
SC - Seychelles 40
RU - Federazione Russa 38
PH - Filippine 34
ID - Indonesia 30
PL - Polonia 22
TH - Thailandia 22
AR - Argentina 21
MX - Messico 19
TG - Togo 18
AT - Austria 17
BG - Bulgaria 17
BE - Belgio 16
CO - Colombia 14
ES - Italia 12
GH - Ghana 12
TW - Taiwan 11
ZA - Sudafrica 11
IQ - Iraq 10
TR - Turchia 10
AU - Australia 9
CH - Svizzera 9
CL - Cile 8
EC - Ecuador 8
JO - Giordania 8
VE - Venezuela 8
GR - Grecia 7
LT - Lituania 6
PK - Pakistan 6
UA - Ucraina 6
AE - Emirati Arabi Uniti 5
JM - Giamaica 5
CZ - Repubblica Ceca 4
KE - Kenya 4
MA - Marocco 4
MY - Malesia 4
NP - Nepal 4
SA - Arabia Saudita 4
TN - Tunisia 4
AL - Albania 3
EG - Egitto 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GT - Guatemala 2
HN - Honduras 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
MD - Moldavia 2
MU - Mauritius 2
NG - Nigeria 2
SN - Senegal 2
AO - Angola 1
BB - Barbados 1
BY - Bielorussia 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
DZ - Algeria 1
HU - Ungheria 1
KW - Kuwait 1
LU - Lussemburgo 1
LY - Libia 1
MG - Madagascar 1
MM - Myanmar 1
MN - Mongolia 1
OM - Oman 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.373
Salva come PNG Salva come JPEG
Città #
Singapore 859
Hong Kong 450
San Jose 414
Ho Chi Minh City 316
Hanoi 312
Ashburn 307
Hefei 299
Santa Clara 165
Los Angeles 152
Seoul 128
Council Bluffs 104
Chandler 96
Beijing 87
New York 81
Boardman 74
Bologna 64
Da Nang 59
Lauterbourg 58
Buffalo 55
Helsinki 53
Abidjan 46
Dublin 43
Dallas 42
Haiphong 42
Krefeld 41
Southend 37
Tokyo 36
Munich 33
Rome 33
Amsterdam 31
Frankfurt am Main 31
São Paulo 30
Milan 29
Princeton 28
Bengaluru 27
Fairfield 27
Falkenstein 26
Shanghai 23
Lappeenranta 22
Chicago 20
Jakarta 19
Lomé 18
Redondo Beach 18
Seattle 18
Nuremberg 17
Sofia 17
Guangzhou 16
Hải Dương 16
Bad Bellingen 15
San Francisco 14
Shenzhen 14
Turin 14
Brussels 13
Houston 13
Warsaw 13
Des Moines 12
Toronto 12
Wilmington 12
Accra 11
Cambridge 11
Woodbridge 11
Bangkok 10
Berlin 10
Düsseldorf 10
London 10
Mexico City 10
Brooklyn 9
Genoa 9
Montreal 9
Naples 9
Ninh Bình 9
Rio de Janeiro 9
Thái Nguyên 9
Tongling 9
Amman 8
Bắc Ninh 8
Can Tho 8
Orem 8
San Diego 8
Biên Hòa 7
Bắc Giang 7
Fort Worth 7
Ha Long 7
Hangzhou 7
Nha Trang 7
Stockholm 7
Trento 7
Ann Arbor 6
Bexley 6
Bến Tre 6
Denver 6
Hillsboro 6
Monzuno 6
Moscow 6
Nanjing 6
Phoenix 6
Quận Bình Thạnh 6
Điện Bàn 6
Athens 5
Bern 5
Totale 5.378
Salva come PNG Salva come JPEG
Nome #
Impact of Somatic DNA Repair Mutations on the Clinical Outcomes of Bone Metastases from Castration-Resistant Prostate Cancer 282
Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer 215
Inherited Mutations in DNA Damage Repair Genes in Italian Men with Metastatic Prostate Cancer: Results from the Meet-URO 10 Study 201
Immunotherapy and its development for gynecological (Ovarian, endometrial and cervical) tumors: From immune checkpoint inhibitors to chimeric antigen receptor (car)-T cell therapy 193
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives 182
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer 175
Clinical Impact of Next-Generation Sequencing Multi-Gene Panel Highlighting the Landscape of Germline Alterations in Ovarian Cancer Patients 173
Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer 170
Advanced low grade serous ovarian cancer: A retrospective analysis of surgical and chemotherapeutic management in two high volume oncological centers 169
Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging 168
Real-World Outcomes and Molecular Profiling for Patients with Metastatic Castration-resistant Prostate Cancer with Lung Metastases: A Long-term Multicenter Experience 165
Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies 157
Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications 156
Ki67 and PR in patients treated with CDK4/6 Inhibitors: A real-world experience 155
Prolonged exposure to (R)-bicalutamide generates a LNCaP subclone with alteration of mitochondrial genome 154
Oligometastatic breast cancer and metastasis-directed treatment: an aggressive multimodal approach to reach the cure 152
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer 148
Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives 147
Combining liquid biopsy and functional imaging analysis in metastatic castration-resistant prostate cancer helps predict treatment outcome 146
Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without 223Ra. 138
Circulating inflammatory cells in patients with metastatic breast cancer: Implications for treatment 128
Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study 125
Moving beyond parp inhibition: Current state and future perspectives in breast cancer 123
Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond 121
Locoregional treatment of de novo stage IV breast cancer in the era of modern oncology 120
Potential Impact of Preoperative Circulating Biomarkers on Individual Escalating/de-Escalating Strategies in Early Breast Cancer 115
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study 111
Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide 108
Circulating tumor DNA fraction (ctDNA) as a surrogate predictive biomarker in metastatic castration-resistant prostate cancer (mCRPC) 108
CAR-T cell therapy: A potential new strategy against prostate cancer 103
Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer 103
Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer 103
Testosterone levels and androgen receptor copy number variations in castration-resistant prostate cancer treated with abiraterone or enzalutamide 97
Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide 97
Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy 96
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients 96
Caregiver emotional burden in testicular cancer patients: From patient to caregiver support 95
An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA 91
New prognostic biomarkers in metastatic castration-resistant prostate cancer 91
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial 89
Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy 89
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: A position paper of the MeetURO Group 87
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer 86
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 85
Circulating androgen receptor (AR) gene amplification and resistance to 177Lu-PSMA-617 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of a phase II clinical trial 85
The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer 85
Hydroxychloroquine as Prophylaxis for COVID-19: A Review 84
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study 81
Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics 81
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma 78
Real-world experience and clinical impact of drug-drug interactions in HR+/HER2- advanced breast cancer patients treated with abemaciclib plus endocrine therapy: the AB-ITALY study 78
Post-traumatic stress symptoms in long-term disease-free cancer survivors and their family caregivers 78
Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 77
Reclassification of good-risk seminoma: Prognostic factors, novel biomarkers and implications for clinical management 75
Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors 75
PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis 75
Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives 74
Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab 72
Immunotherapy for prostate cancer: Where we are headed 66
A comprehensive review of the role of immune checkpoint inhibitors in elderly patients affected by renal cell carcinoma 65
Endometriosis and endometrial cancer: A propensity score-adjusted real-world data study 63
Correlation of [68Ga]Ga-PSMA PET/CT response and clinical outcomes in patients treated with enzalutamide as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective study 63
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/ HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial 63
Risk of Myelodysplastic Syndrome and Acute Myeloid Leukemia related to PARP inhibitor Maintenance Line in Real-world Ovarian Cancer Patients 62
Human chorionic gonadotropin–positive seminoma patients: A registry compiled by the global germ cell tumor collaborative group (G3) 61
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer 61
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy? 60
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer 60
Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature 58
Addition of androgen receptor targeted agents to androgen deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis 57
Reply to comments on: Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients 56
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer 53
A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group 53
Inflammatory Biomarkers for Outcome Prediction in Patients With Metastatic Testicular Cancer 53
Bevacizumab as maintenance treatment in patients with ovarian cancer: Wait for BRCA testing 51
Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA 51
Immune system and DNA repair defects in ovarian cancer: Implications for locoregional approaches 48
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk breast cancer: results from the italian National Registry 42
Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients 40
Survey on cancer patients’ attitudes towards AI and data protection: A cross-sectional study from an Italian cancer center 40
Psychosocial issues in long-term survivors of testicular cancer 39
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21) 36
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 34
Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2–positive early breast cancer: real–world data from NeoPowER study 34
Corrigendum to “Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives” [Crit. Rev. Oncol./Hematol. 181 (2023) 103900] (Critical Reviews in Oncology / Hematology (2023) 181, (S1040842822003249), (10.1016/j.critrevonc.2022.103900)) 33
Role of Bone Metastases in Patients Receiving Immunotherapy for Pre-Treated Urothelial Carcinoma: The Multicentre, Retrospective Meet-URO-1 Bone Study 27
Pharmacological CDK4/6 inhibition promotes vulnerability to lysosomotropic agents in breast cancer 23
Corrigendum to “Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond” [Crit. Rev. Oncol./Hematol. 200C (2024) 104404](S1040842824001471)(10.1016/j.critrevonc.2024.104404) 21
Vitamin D Deficiency in Testicular Cancer Survivors: A Systematic Review 16
Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors 15
Therapeutic challenges for cisplatin-resistant ovarian germ cell tumors 15
Pharmacokinetics, pharmacodynamics and clinical efficacy of nivolumab in the treatment of metastatic renal cell carcinoma 15
Castration-resistant prostate cancer with bone metastases: toward the best therapeutic choice 11
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors 10
null 2
Totale 8.568
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.745
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.745
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202122 0 0 0 0 0 0 0 0 0 0 0 22
2021/2022234 4 0 3 6 9 4 25 16 5 50 74 38
2022/2023343 20 48 11 47 22 44 8 16 72 9 20 26
2023/2024364 10 17 5 3 9 39 15 15 204 21 17 9
2024/20251.699 100 207 121 152 230 108 52 68 17 138 101 405
2025/20265.793 357 423 386 363 452 117 1.238 347 1.044 458 383 225
Totale 8.568